Lessons Learned from Faecal Microbiota Transplantation in Cirrhosis

AbstractPurpose of ReviewWe examine recent developments in the treatment of cirrhosis by gut microbiome manipulation specifically focusing on the phase 1 safety and feasibility trials of faecal microbiota transplantation (FMT). We interrogate the published data so far on its feasibility, safety and efficacy.Recent FindingsA large number of trials have demonstrated the efficacy of FMT in treating recurrentClostridium difficile infection which is now considered standard of care. In cirrhosis, FMT is still being evaluated and there are a number of clinical trials underway. There are two phase 1 pilot safety studies that have been published with promising findings. However, the importance of rigorously testing donor stool for the presence of multi-drug resistant species has been highlighted and lessons have been learned.SummaryFor those patients with cirrhosis, replacing an unhealthy gut microbiome with a healthy one offers a promising antibiotic-free treatment that may reduce bacterial translocation and endotoxemia.

Source: Current Hepatitis Reports - June 23, 2020 Category: Infectious Diseases Source Type: research